AMENDMENTS TO THE CLAIMS:

Please cancel claims 113-120, 122, 124-125, 132-139, 141, 143-144, and 152, and amend claims 112, 126, 131, 145, 146, and 151, as shown in the following listing of claims, which will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-111. Cancelled.
- 112. (Currently amended) A vector system for producing infectious virus particles having a characteristic of BAAV, the system comprising:
 - (a) a pair of BAAV inverted terminal repeats <u>nucleotide</u> sequence comprising SEQ ID NO:12; and,
 - (b) at least one nucleic acid sequence selected from the group consisting of:
 - (i) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11; and,
 - (ii) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:3, and SEQ ID NO:5.
 - 113-120. (Canceled)
- 121. (Previously presented) The vector system of claim 112, wherein the nucleic acid sequence of (b) is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:10.
 - 122. (Canceled)
- 123. (Currently amended) The vector system of claim 112, wherein the nucleic acid sequence of (eb) is selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:4.
 - 124-125. (Canceled)
- 126. (Currently amended) The vector system of claim 112, wherein the at least one vector comprises a pair of inverted terminal repeats, and wherein the vector further nucleotide sequence comprising SEQ ID NO:12 comprises a promoter between the BAAV inverted terminal repeats.

- 127. (Previously presented) The vector system of claim 126, wherein the promoter is functionally linked to an exogenous nucleic acid sequence.
- 128. (Previously presented) The vector system of claim 112, wherein a vector of the vector system is encapsidated in an AAV particle.
- 129. (Previously presented) The vector system of claim 128, wherein the vector is encapsidated in a dependent parvovirus particle.
- 130. (Previously presented) The vector system of claim 129, wherein the parvovirus particle is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle, an AAV5 particle, an AAV6 particle, an AAV7 particle, an AAV8 particle, an AAAV particle, or a BAAV particle.
 - 131. (Currently amended) A vector system comprising: at least two vectors, wherein

 (a) a first vector comprises comprising at least one a nucleic acid sequence selected from the group consisting of:
 - (ai) a nucleic acid sequence encoding a capsid protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11; and,
 - (bii) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:3, and SEQ ID NO:5; and,
 - (b) wherein a second vector comprising comprises a pair of BAAV inverted terminal repeats a nucleotide sequence comprising SEQ ID NO:12.
 - 132-139. (Canceled)
- 140. (Previously presented) The vector system of claim 131, wherein the nucleic acid sequence of (a) is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:10.
 - 141. (Canceled)
- 142. (Currently amended) The vector system of claim 131, wherein the nucleic acid sequence of (ba) is selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:4.
 - 143-144. (Canceled)

- 145. (Currently) The vector system of claim 131, wherein the first vector comprises:
- (a) a nucleic acid sequence encoding a capsid protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11; and,
- (b) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:3, and SEQ ID NO:5.
- 146. (Currently amended) The vector system of claim 131, wherein the second vector further the nucleotide sequence comprising SEQ I DNO:12 comprises a promoter between the BAAV inverted terminal repeats.
- 147. (Previously presented) The vector system of claim 146, wherein the promoter is functionally linked to an exogenous nucleic acid sequence.
- 148. (Previously presented) The vector system of claim 131, wherein a vector of the vector system is encapsidated in an AAV particle.
- 149. (Previously presented) The vector system of claim 148, wherein the vector is encapsidated in a dependent parvovirus particle.
- 150. (Previously presented) The vector system of claim 149, wherein the parvovirus particle is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle, an AAV5 particle, an AAV6 particle, an AAV7 particle, an AAV8 particle, an AAAV particle, or a BAAV particle.
- 151. (Currently amended) A vector system for producing infectious virus particles having a characteristic of BAAV, the system comprising at least one vector comprising (a) the nucleotide sequence of SEQ ID NO:12, and (b) a nucleic acid sequence encoding a protein selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11:
 - (a) a pair of BAAV inverted terminal repeats, wherein at least one ITR is at least 96% identical to SEQ ID NO:12; and,
 - (b) a nucleic acid sequence encoding a protein comprising an amino acid sequence selected from the group consisting of
 - (i) an amino acid sequence at least 97% identical to a sequence selected from the group consisting of SEQ ID NO:7;

- (ii) an amino acid sequence at least 97% identical to SEQ ID NO:9; and,
- (iii) an amino acid sequence at least 99% identical to SEQ ID NO:11; and,
- (c) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:3, and SEQ ID NO:5.
- 152. (Canceled)